Please assess the completion status of the following clinical trial:

Trial Title: Methylphenidate for Attention Problems After Pediatric TBI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between ages of 6-17~* Sustained Moderate to Severe TBI~* TBI occurred at least 6 months prior to beginning the study~* TBI occurred no earlier than 5 years of age~* Positive endorsement of 6 out of 9 items on the Vanderbilt ADHD inattention or hyperactivity scale~Exclusion Criteria:~* History of developmental disability or mental retardation~* Current active participation in ADHD-related behavioral intervention~* History of psychiatric condition requiring an inpatient admission in past 12 months~* Actively taking medications with a contraindication to Concerta that cannot be discontinued~* Current use of stimulant medication or ADHD specific medications that cannot be discontinued~* Non-blunt head injury~* Family history of arrhythmia~* Pregnancy

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Methylphenidate (Type: EXPERIMENTAL): The study medication will consist of identical capsules filled Concerta® over-encapsulated to preserve double-blinding. The weekly dosages will be low, medium, and high based on weight cut-offs. Participants weighing less than 25kg will receive 18mg (low), 27mg (medium), and 36mg (high) dosages and participants weighing above 25kg will receive 18mg (low), 36mg (medium), and 54mg (high) dosages during the 3-week upward titration trial. Weekly ratings monitoring behavioral and side effect symptoms score and the Pittsburgh Side Effects Rating Scale.
- Placebo (Type: PLACEBO_COMPARATOR): The study medication will consist of identical capsules filled with an inert white power (placebo). Weekly ratings monitoring behavioral and side effect symptoms score and the Pittsburgh Side Effects Rating Scale.

Based on this trial design, predict the completion outcome and termination type (if applicable).